{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:47:32Z","timestamp":1793944052316,"version":"4.8.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005187","name":"National and Kapodistrian University of Athens","doi-asserted-by":"publisher","award":["11123"],"award-info":[{"award-number":["11123"]}],"id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.autrev.2020.102491","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T22:02:21Z","timestamp":1582063341000},"page":"102491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study"],"prefix":"10.1016","volume":"19","author":[{"given":"Evrydiki","family":"Kravvariti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Koutsogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Samoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102491_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2020.102491_bb0010","first-page":"1","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102491_bb0015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102491_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-016-0566-z","article-title":"Emerging therapies in antiphospholipid syndrome","volume":"18","author":"Andrade","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2020.102491_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2014.12.006","article-title":"Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome","author":"Belizna","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102491_bb0030","doi-asserted-by":"crossref","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2020.102491_bb0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102491_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","author":"Tektonidou","year":"2009","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2020.102491_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","author":"Petri","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2020.102491_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3899\/jrheum.120157","article-title":"Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and\/or lupus anticoagulant in systemic lupus erythematosus","volume":"40","author":"Broder","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102491_bb0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","volume":"65","author":"Nuri","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2020.102491_bb0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2020.102491_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.96.12.4380","article-title":"Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice","author":"Edwards","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2020.102491_bb0070","doi-asserted-by":"crossref","DOI":"10.1055\/s-0037-1613033","article-title":"Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies","author":"Espinola","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2020.102491_bb0075","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","article-title":"Hydroxychloroquine directly reduces the bindin of antiphospholipid antibody-\u03b22-glycoprotein I complexes to phospholipid bilayers","volume":"112","author":"Rand","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102491_bb0080","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2020.102491_bb0085","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","article-title":"A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome","volume":"41","author":"Erkan","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102491_bb0090","doi-asserted-by":"crossref","DOI":"10.1177\/0961203317724219","article-title":"Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease","author":"Erkan","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2020.102491_bb0095","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection","volume":"7","author":"Pengo","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"1725","key":"10.1016\/j.autrev.2020.102491_bb0100","article-title":"Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102491_bb0105","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2020.102491_bb0110","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","author":"Ruffatti","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102491_bb0115","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on Antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2020.102491_bb0120","article-title":"Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals","volume":"31","author":"Gir\u00f3n-Gonz\u00e1lez","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102491_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.02.003","article-title":"The treatment of anti-phospholipid syndrome: a comprehensive clinical approach","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2020.102491_bb0130","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102491_bb0135","series-title":"Seventh International Congress on SLE and Related Conditions Abstract book","article-title":"Use of hydroxychloroquine in antiphospholipid antibody syndrome at three academic rheumatology units over two years: improvement in antibody titer and symptom management [abstract]","volume":"M17A","author":"McCarty","year":"2004"},{"key":"10.1016\/j.autrev.2020.102491_bb0140","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.autrev.2015.04.010","article-title":"Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?","volume":"14","author":"De Carolis","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102491_bb0145","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/ard.2004.031856","article-title":"Real world experience with antiphospholipid antibody tests: how stable are results over time?","volume":"64","author":"Erkan","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102491_bb0150","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jth.13379","article-title":"IgG\/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis","volume":"14","author":"Kelchtermans","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2020.102491_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0212614","article-title":"Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: role of reduced inflammation and endothelial dysfunction","volume":"14","author":"Miranda","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2020.102491_bb0160","first-page":"120","article-title":"The effect of hydroxychloroquine on haemostasis, Complement, Inflammation and angiogenesis in patients with antiphospholipid antibodies","volume":"57","author":"Schreiber","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.autrev.2020.102491_bb0165","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexinA5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","author":"Rand","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102491_bb0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/aji.12184","article-title":"Effect of Hydroxychloroquine on Antiphospholipid antibody-induced changes in first trimester Trophoblast function","volume":"71","author":"Albert","year":"2014","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.autrev.2020.102491_bb0175","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and Imidazoquinolines","volume":"186","author":"Ku\u017enik","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102491_bb0180","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102491_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102311","article-title":"Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications","author":"Xourgia","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2020.102491_bb0190","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/ATVBAHA.108.162289","article-title":"Mechanisms of venous thrombosis and resolution","volume":"28","author":"Wakefield","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2020.102491_bb0195","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.autrev.2018.05.012","article-title":"HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome","volume":"17","author":"Belizna","year":"2018","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:18:02Z","timestamp":1761599882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220300392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1568997220300392"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102491","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102491"}}